Sterol/stanol phosphorylnitroderivatives and use thereof
Sterol and stanol phosphorylnitro derivatives and their use in treating or preventing cardiovascular disease, its underlying conditions and other disorders are disclosed. The disclosed compounds include a phosphate linker, at least one moiety that releases nitric oxide (NO), and a sterol or stanol moiety. Some compounds additionally include an ascorbyl moiety to make the compound more readily soluble in aqueous and non-aqueous media.
1. Sterol and/or stanol nitroderivatives, including pharmaceutically acceptable salts and stereoisomers thereof, represented by the general formulae:
wherein in the foregoing formulae, R is selected from CH 3 and CH 2 CH 3 and R 1 is an aromatic or aliphatic NO releasing agent selected from the group consisting of:
wherein n is an integer from 1 to 20.
2. Sterol and/or stanol nitroderivatives, including pharmaceutically acceptable salts and stereoisomers thereof, represented by the general formulae:
wherein in the foregoing formulae, R is selected from CH 3 and CH 2 CH 3 and R 1 and R 2 are aromatic or aliphatic NO releasing agents and are independently selected from the group consisting of:
and wherein n is an integer from 1 to 20.
3. Sterol and/or stanol nitroderivatives, including pharmaceutically acceptable salts and stereoisomers thereof, represented by the general formulae:
wherein R is either CH 3 or CH 2 CH 3 ; and
a) one of R 1 , R 2 , R 3 or R 4 is an aliphatic or aromatic NO releasing agent selected from the group consisting of:
wherein n is an integer from 1 to 20 and the remaining three groups of R 1 , R 2 , R 3 or R 4 are OH; or
b) one of R 1 , R 2 , R 3 or it is an aliphatic or aromatic NO releasing agent selected from the group consisting of:
wherein n is an integer from 1 to 20 and the remaining three groups of R 1 , R 2 , R 3 or R 4 are OH.
4. Sterol and/or stanol nitroderivatives, including pharmaceutically acceptable salts and stereoisomers thereof, represented by the general formulae:
wherein R is either CH 3 or CH 2 CH 3 ; and
a) any two of R 1 , R 2 , R 3 or R 4 is selected from the group consisting of:
wherein n is an integer from 1 to 20 and the remaining groups of R 1 , R 2 , R 3 or R 4 are OH; or
b) any two of R 1 , R 2 , R 3 or R 4 is selected from the group consisting of:
wherein n is an integer from 1 to 20 and the remaining groups of R 1 , R 2 , R 3 or R 4 are OH.
5. Sterol and/or stanol nitroderivatives, including pharmaceutically acceptable salts and stereoisomers thereof, represented by the general formulae:
wherein R is either CH 3 or CH 2 CH 3 and
a) R 1 and R 2 are selected from the following:
or
b) ) R 1 is H and R 2 is selected from the three compounds noted below:
and wherein n is an integer from 1 to 20.
6. The nitroderivatives of claim 1 wherein the sterol and stanol are selected from the group consisting of sitosterol, campesterol, stigmasterol, brassicasterol, desmosterol, chalinosterol, poriferasterol, clionasterol, sitostanol, campestanol, stigmastanol, brassicastanol, desmostanol, chalinostanol, poriferastanol, and clionastanol.
7. Pharmaceutical compositions comprising the sterol and/or stanol nitroderivatives of claim 1 and one or more suitable caffiers, excipients or adjuvants.
8. The sterol/stanol nitroderivatives of claim 1 wherein the sterol and stanol are in either a natural or synthesized form.
9. The sterol/stanol nitroderivatives of claim 1 wherein the sterol and stanol are in any one of their isomeric forms.
10. The sterol/stanol nitroderivatives of claim 1 wherein the sterol/stanol is selected from the group consisting of sitostanol, sitosterol, campestanol and campesterol.
11. Pharmaceutical compositions comprising the sterol/stanol nitroderivatives of claim 1 and at least one agent which reduces cholesterol synthesis in humans.
12. The pharmaceutical compositions of claim 11 wherein the agent is a 3-hydroxy-3-methyl glutaryl coenzyme-A (HMG-CoA) reductase inhibitor.
13. Pharmaceutical compositions comprising the sterol/stanol nitroderivatives of claim 1 additionally comprising one or more of the following: ACE inhibitors, angiotensin II receptor antogonists, beta-andrenergic blockers, calcium channel blockers, and anti-thrombotics.
14. The pharmaceutical composition of claim 13 , wherein anti-thrombotics are selected from aspirin, nitrosated ACE inhibitors, nitrosated angiotensin II receptor antogonists, nitrosated beta-andrenergic blockers, and nitrosated aspirin.